Mueller, Juliane K. and Ahrens, Kira F. and Bauer, Michael and Baune, Bernhard T. and Borgwardt, Stefan and Deckert, Juergen and Domschke, Katharina and Ellwanger, Regina and Fallgatter, Andreas and Frodl, Thomas and Gallinat, Juergen and Gottschalk, Rene and Grabe, Hans J. and Hasan, Alkomiet and Herpertz, Sabine C. and Hurlemann, Rene and Jessen, Frank and Kambeitz, Joseph and Kircher, Tilo and Kornhuber, Johannes and Lieb, Klaus and Meyer-Lindenberg, Andreas and Rupprecht, Rainer and Scherbaum, Norbert and Schlang, Christiane and Schneider, Anja and Schomerus, Georg and Thoma, Andreas and Unterecker, Stefan and Walter, Martin and Walter, Henrik and Reif, Andreas and Reif-Leonhard, Christine (2023) Prevalence of COVID-19 and Psychotropic Drug Treatment in Psychiatric In-patients in Germany in 2020: Results from a Nationwide Pilot Survey. PHARMACOPSYCHIATRY, 56 (06). pp. 227-238. ISSN 0176-3679, 1439-0795
Full text not available from this repository. (Request a copy)Abstract
Introduction In patients with a pre-existing mental disorder, an increased risk for a first manifestation of a psychiatric disorder in COVID-19 patients, a more severe course of COVID-19 and an increased mortality have been described. Conversely, observations of lower COVID-19 incidences in psychiatric in-patients suggested protective effects of psychiatric treatment and/or psychotropic drugs against COVID-19.Methods A retrospective multi-center study was conducted in 24 German psychiatric university hospitals. Between April and December 2020 (the first and partly second wave of COVID-19), the effects of COVID-19 were assessed on psychiatric in-patient care, the incidence and course of a SARS-CoV-2 infection, and treatment with psychotropic drugs.Results Patients (n=36,322) were admitted to the hospitals. Mandatory SARS-CoV-2 tests before/during admission were reported by 23 hospitals (95.8%), while 18 (75%) conducted regular testing during the hospital stay. Two hundred thirty-two (0.6%) patients were tested SARS-CoV-2-positive. Thirty-seven (16%) patients were receiving medical treatment for COVID-19 at the psychiatric hospital, ten (4.3%) were transferred to an intermediate/intensive care unit, and three (1.3%) died. The most common prescription for SARS-CoV-2-positive patients was for second-generation antipsychotics (n=79, 28.2%) and antidepressants (SSRIs (n=38, 13.5%), mirtazapine (n=36, 12.9%) and SNRIs (n=29, 10.4%)).Discussion Contrary to previous studies, our results showed a low number of infections and mortality in SARS-CoV-2-positive psychiatric patients. Several preventive measures seem effective to protect this vulnerable group. Our observations are compatible with the hypothesis of a protective effect of psychotropic drugs against COVID-19 as the overall mortality and need for specific medical treatment was low.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | MENTAL-DISORDERS; SUBSTANCE USE; OUTCOMES; METAANALYSIS; INFECTION; RISK; CARE; MANIFESTATIONS; COMORBIDITIES; DEPRESSION; COVID-19; psychiatry; psychotropic drugs; SARS-CoV-2 |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Psychiatrie und Psychotherapie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 30 Jan 2024 14:34 |
| Last Modified: | 30 Jan 2024 14:34 |
| URI: | https://pred.uni-regensburg.de/id/eprint/60913 |
Actions (login required)
 |
View Item |
